Found 71 clinical trials
GOG 0213: A Phase III, Randomized, Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer. NCI-SUPPLIED AGENTS: BEVACIZUMAB.
GOG 0213: A Phase III, Randomized, Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in
- 690 views
- 08 Nov, 2020
- 1 location
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
- 104 views
- 12 Aug, 2022
- 17 locations
TAP and IMS for HIPEC
It is important to decrease the postoperative pain in patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. We will compare the Transversus abdominis plane
- 0 views
- 01 May, 2022
- 1 location
Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients (ACAPP)
This is a phase II, mono institutional, non comparative study, evaluating adjuvant capecitabine in patients affected by KRAS mutated Pseudomyxoma peritonei treated with cytoreductive surgery and
- 0 views
- 27 Apr, 2022
- 1 location
Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer
hypothesis considers that using Hyperthermic Intra-abdominal Chemotherapy,HIPEC, with gemcitabine after cytoreductive surgery ,will decrease tumor progression of pancreatic cancer by reducing the neoplastic
- 30 views
- 31 Jan, 2022
- 1 location
PIPAC in Multimodal Therapy for Patients With Oligometastatic Peritoneal Gastric Cancer (PIPAC_VEROne)
the prognosis is very poor. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) resulted in long-term benefits in selected patients with limited peritoneal
- 0 views
- 24 Jul, 2022
- 1 location
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer (IPLA-OVCA)
intraperitoneal local anaesthetics administered perioperatively during 72 h leads to early start of chemotherapy compared to placebo in patients undergoing cytoreductive surgery for FIGO stage III-IV ovarian
- 0 views
- 11 Jul, 2022
- 1 location
NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK)
advanced ovarian cancer consist of cytoreductive surgery and platinum-based chemotherapy with or without concurrent and maintenance bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor.
- 0 views
- 05 May, 2022
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (OVHIPEC-2)
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
- 0 views
- 05 Jun, 2022
- 19 locations
Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis
The purpose of this study is to determine the efficacy of adjuvant HIPEC with Mitomycin C after colectomy in the treatment of colorectal cancer patients at high risk of peritoneal carcinomatosis.
- 15 views
- 25 Jan, 2021
- 33 locations